Patents by Inventor David Ginsburg
David Ginsburg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9504688Abstract: The present invention relates to chemical compounds, methods for their discovery, and their therapeutic and research use. In particular, the present invention provides compounds as therapeutic agents against bacterial infections (e.g., biofilms).Type: GrantFiled: May 2, 2013Date of Patent: November 29, 2016Assignees: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, THE CURATORS OF THE UNIVERSITY OF MISSOURIInventors: David Ginsburg, Scott D. Larsen, Bryan Yestrepsky, Hongmin Sun
-
Publication number: 20150213295Abstract: Methods and systems for monitoring the location of animate and inanimate objects include tags operatively connected to the object configured for wireless communication with one or more hubs within a monitoring site. The tags may send preemptive identifying signals to the hubs when in a range of communication using Bluetooth Low Energy signals. The hubs may register with the tags within a certain location and send status signals over a network. The status signals may be used to monitor the location of the objects and tags, and may be used to generate messages indicating location information of the objects. Cloud based computing may be used to run applications and databases to monitor and share tag location information.Type: ApplicationFiled: January 26, 2015Publication date: July 30, 2015Inventors: David Ginsburg, Alan Simon
-
Publication number: 20150132352Abstract: The present invention relates to chemical compounds, methods for their discovery, and their therapeutic and research use. In particular, the present invention provides compounds as therapeutic agents against bacterial infections (e.g., biofilms).Type: ApplicationFiled: May 2, 2013Publication date: May 14, 2015Inventors: Hongmin Sun, Bryan Yestrepsky, David Ginsburg, Scott D. Larsen
-
Patent number: 8597910Abstract: Von Willebrand's Factor (VWF) is produced using an expression vector that includes: 1) a DNA sequence encoding a functional VWF protein; and 2) regulatory DNA capable of effecting expression of that DNA sequence in a host cell transformed with the vector. Restriction fragment length polymorphisms (RFLP's) associated with the VWF gene are identified and used in a probe for determining the source of a VWF gene in a DNA sample. The gene for VWF is localized to the short arm of human chromosome 12 (12p).Type: GrantFiled: July 23, 1990Date of Patent: December 3, 2013Assignee: Children's Medical Center CorporationInventors: David Ginsburg, Stuart H. Orkin, Randal J. Kaufman
-
Patent number: 8501722Abstract: The present invention relates to chemical compounds, methods for their discovery, and their therapeutic and research use. In particular, the present invention provides compounds as therapeutic agents against bacterial infections.Type: GrantFiled: January 21, 2010Date of Patent: August 6, 2013Assignee: The Regents of the University of MichiganInventors: David Ginsburg, Hongmin Sun, Scott Larsen, Bryan Yestrepsky
-
Patent number: 8394373Abstract: The present invention relates to a disintegrin and metalloproteinase containing thrombospondin 1-like domains (ADAMTS) and in particular to a novel ADAMTS13 protease and to nucleic acids encoding ADAMTS13 proteases. The present invention encompasses both native and recombinant wild-type forms of ADAMTS13, as well as mutant and variant forms including fragments, some of which posses altered characteristics relative to the wild-type ADAMTS13. The present invention also relates to methods of using ADAMTS13, including for treatment of TTP. The present invention also relates to methods for screening for the presence of TTP. The present invention further relates to methods for developing anticoagulant drugs based upon ADAMTS13.Type: GrantFiled: April 13, 2009Date of Patent: March 12, 2013Assignee: The Regents of the University of MichiganInventors: David Ginsburg, Gallia Levy, Han-Mou Tsai
-
Patent number: 8273714Abstract: The present invention relates to a disintegrin and metalloproteinase containing thrombospondin 1-like domains (ADAMTS) and in particular to a novel ADAMTS13 protease and to nucleic acids encoding ADAMTS13 proteases. The present invention encompasses both native and recombinant wild-type forms of ADAMTS13, as well as mutant and variant forms including fragments, some of which posses altered characteristics relative to the wild-type ADAMTS13. The present invention also relates to methods of using ADAMTS13, including for treatment of TTP. The present invention also relates to methods for screening for the presence of TTP. The present invention further relates to methods for developing anticoagulant drugs based upon ADAMTS13.Type: GrantFiled: April 13, 2009Date of Patent: September 25, 2012Assignee: The Regents of The University of MichiganInventors: David Ginsburg, Gallia Levy, Han-Mou Tsai
-
Publication number: 20100331351Abstract: The present invention relates to chemical compounds, methods for their discovery, and their therapeutic and research use. In particular, the present invention provides compounds as therapeutic agents against bacterial infections.Type: ApplicationFiled: January 21, 2010Publication date: December 30, 2010Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: David Ginsburg, Hongmin Sun, Scott Larsen, Bryan Yestrepsky
-
Patent number: 7662946Abstract: The present invention relates to a disintegrin and metalloproteinase containing thrombospondin 1-like domains (ADAMTS) and in particular to a novel ADAMTS13 protease and to nucleic acids encoding ADAMTS13 proteases. The present invention encompasses both native and recombinant wild-type forms of ADAMTS13, as well as mutant and variant forms including fragments, some of which posses altered characteristics relative to the wild-type ADAMTS13. The present invention also relates to methods of using ADAMTS13, including for treatment of TTP. The present invention also relates to methods for screening for the presence of TTP. The present invention further relates to methods for developing anticoagulant drugs based upon ADAMTS13.Type: GrantFiled: March 17, 2006Date of Patent: February 16, 2010Assignee: The Regents of the University of MichiganInventors: David Ginsburg, Gallia Levy, Han-Mou Tsai
-
Publication number: 20090304672Abstract: The present invention relates to a disintegrin and metalloproteinase containing thrombospondin 1-like domains (ADAMTS) and in particular to a novel ADAMTS13 protease and to nucleic acids encoding ADAMTS13 proteases. The present invention encompasses both native and recombinant wild-type forms of ADAMTS13, as well as mutant and variant forms including fragments, some of which posses altered characteristics relative to the wild-type ADAMTS13. The present invention also relates to methods of using ADAMTS13, including for treatment of TTP. The present invention also relates to methods for screening for the presence of TTP. The present invention further relates to methods for developing anticoagulant drugs based upon ADAMTS13.Type: ApplicationFiled: April 13, 2009Publication date: December 10, 2009Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: David Ginsburg, Gallia Levy, Han-Wou Tsai
-
Publication number: 20090274683Abstract: The present invention relates to a disintegrin and metalloproteinase containing thrombospondin 1-like domains (ADAMTS) and in particular to a novel ADAMTS13 protease and to nucleic acids encoding ADAMTS13 proteases. The present invention encompasses both native and recombinant wild-type forms of ADAMTS13, as well as mutant and variant forms including fragments, some of which posses altered characteristics relative to the wild-type ADAMTS13. The present invention also relates to methods of using ADAMTS13, including for treatment of TTP. The present invention also relates to methods for screening for the presence of TTP. The present invention further relates to methods for developing anticoagulant drugs based upon ADAMTS13.Type: ApplicationFiled: April 13, 2009Publication date: November 5, 2009Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: David Ginsburg, Gallia Levy, Han-Mou Tsai
-
ADAMTS13 genes and proteins and variants and therapeutic compositions and methods utilizing the same
Patent number: 7517522Abstract: The present invention relates to a disintegrin and metalloproteinase containing thrombospondin 1-like domains (ADAMTS) and in particular to a novel ADAMTS13 protease and to nucleic acids encoding ADAMTS13 proteases. The present invention encompasses both native and recombinant wild-type forms of ADAMTS13, as well as mutant and variant forms including fragments, some of which posses altered characteristics relative to the wild-type ADAMTS13. The present invention also relates to methods of using ADAMTS13, including for treatment of TTP. The present invention also relates to methods for screening for the presence of TTP. The present invention further relates to methods for developing anticoagulant drugs based upon ADAMTS13.Type: GrantFiled: January 30, 2006Date of Patent: April 14, 2009Assignee: The Regents of the University of MichiganInventors: David Ginsburg, Gallia Levy, Han-Mou Tsai -
Publication number: 20060246589Abstract: The present invention relates to a disintegrin and metalloproteinase containing thrombospondin 1-like domains (ADAMTS) and in particular to a novel ADAMTS13 protease and to nucleic acids encoding ADAMTS13 proteases. The present invention encompasses both native and recombinant wild-type forms of ADAMTS13, as well as mutant and variant forms including fragments, some of which posses altered characteristics relative to the wild-type ADAMTS13. The present invention also relates to methods of using ADAMTS13, including for treatment of TTP. The present invention also relates to methods for screening for the presence of TTP. The present invention further relates to methods for developing anticoagulant drugs based upon ADAMTS13.Type: ApplicationFiled: March 17, 2006Publication date: November 2, 2006Inventors: David Ginsburg, Gallia Levy, Han-Mou Tsai
-
Publication number: 20060233784Abstract: The present invention relates to a disintegrin and metalloproteinase containing thrombospondin 1-like domains (ADAMTS) and in particular to a novel ADAMTS13 protease and to nucleic acids encoding ADAMTS13 proteases. The present invention encompasses both native and recombinant wild-type forms of ADAMTS13, as well as mutant and variant forms including fragments, some of which posses altered characteristics relative to the wild-type ADAMTS13. The present invention also relates to methods of using ADAMTS13, including for treatment of TTP. The present invention also relates to methods for screening for the presence of TTP. The present invention further relates to methods for developing anticoagulant drugs based upon ADAMTS13.Type: ApplicationFiled: January 30, 2006Publication date: October 19, 2006Inventors: David Ginsburg, Gallia Levy, Han-Mou Tsai
-
Patent number: 7037658Abstract: The present invention relates to a disintegrin and metalloproteinase containing thrombospondin 1-like domains (ADAMTS) and in particular to a novel ADAMTS13 protease and to nucleic acids encoding ADAMTS13 proteases. The present invention encompasses both native and recombinant wild-type forms of ADAMTS13, as well as mutant and variant forms including fragments, some of which posses altered characteristics relative to the wild-type ADAMTS13. The present invention also relates to methods of using ADAMTS13, including for treatment of TTP. The present invention also relates to methods for screening for the presence of TTP. The present invention further relates to methods for developing anticoagulant drugs based upon ADAMTS13.Type: GrantFiled: August 16, 2002Date of Patent: May 2, 2006Assignee: Regents of University of MichiganInventors: David Ginsburg, Gallia Levy, Han-Mou Tsai
-
Publication number: 20040259157Abstract: The present invention relates to early secretory pathway molecules, in particular to the MCFD2 (multiple coagulation factor deficiency 2) protein, and nucleic acids encoding the MCFD2 protein. The present invention provides assays for the detection of MCFD2 and for MCFD2 polymorphisms and mutations associated with disease states and provides screening assays for the identification and use of compounds that alter MCFD2 activity and/or biological pathways involving MCFD2.Type: ApplicationFiled: February 18, 2004Publication date: December 23, 2004Inventors: David Ginsburg, Bin Zhang, Randal J. Kaufman
-
Publication number: 20030073116Abstract: The present invention relates to a disintegrin and metalloproteinase containing thrombospondin 1-like domains (ADAMTS) and in particular to a novel ADAMTS13 protease and to nucleic acids encoding ADAMTS13 proteases. The present invention encompasses both native and recombinant wild-type forms of ADAMTS13, as well as mutant and variant forms including fragments, some of which posses altered characteristics relative to the wild-type ADAMTS13. The present invention also relates to methods of using ADAMTS13, including for treatment of TTP. The present invention also relates to methods for screening for the presence of TTP. The present invention further relates to methods for developing anticoagulant drugs based upon ADAMTS13.Type: ApplicationFiled: August 16, 2002Publication date: April 17, 2003Applicant: Regents of the University of MichiganInventors: David Ginsburg, Gallia Levy, Han-Mou Tsai
-
Patent number: 6066778Abstract: The present invention relates to compositions and methods for the screening of compounds for anticoagulant activity. In particular, the present invention relates to non-human transgenic animals expressing activated protein C ("APC")-resistant factor V proteins which display a predisposition toward spontaneous thrombosis. The present invention also provides methods for using these transgenic animals to screen compounds for anticoagulant activity.Type: GrantFiled: November 6, 1996Date of Patent: May 23, 2000Assignee: The Regents of the University of MichiganInventors: David Ginsburg, Jisong Cui
-
Patent number: 5639726Abstract: The invention relates generally to peptides which decrease the half-life of active plasminogen activator inhibitor-1. This invention further relates to methods and compositions for using peptides which decrease the half-life of active plasminogen activator inhibitor-1. Further, the invention includes methods and compositions useful in clot lysis.Type: GrantFiled: September 30, 1994Date of Patent: June 17, 1997Assignees: The Regents of the University of Michigan, Henry Ford Health SystemInventors: Daniel A. Lawrence, David Ginsburg, Joseph D. Shore, William P. Fay, Steven T. Olson, Ann Marie Francis-Chmura, Daniel T. Eitzman, Dell Paielli
-
Patent number: 4789234Abstract: The motion contrast visual sensitivity of an individual is tested by means of a target having thereon patches each composed of alternating light and dark bars, with individual patches varying in contrast and spatial frequency, and also in orientation. The target is viewed by way of a slot through a housing positioned in front of the individual under test, and a shutter rotating within the housing at a controlled speed periodically blocks the slot at a rate sufficiently slow, e.g. 30 cycles per second, for the observer to detect the resulting conditions of flicker.Type: GrantFiled: January 2, 1987Date of Patent: December 6, 1988Assignee: Vistech Consultants, Inc.Inventors: Arthur P. Ginsburg, David A. Ginsburg, Robert P. Ginsburg